文献速递临床试验与 GCP

光凝或假激光联合常规抗VEGF治疗糖尿病黄斑水肿或视网膜静脉阻塞相关毛细血管扩张症黄斑水肿(TalaDME):一项多中心、法国、两组、非商业、活性对照、观察者设盲、非劣效性、随机对照临床试验的研究方案

Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial.
PubMed 文献 · Trials · 2024-04-22

TalaDME是一项法国多中心、随机、假激光对照、双盲、非劣效性试验,计划纳入270例由糖尿病视网膜病变或视网膜静脉阻塞继发黄斑水肿且存在毛细血管扩张症(TelCaps)的患者,比较抗VEGF单药与抗VEGF联合ICG引导靶向激光(IGTL)对第一年注射次数及视力变化的影响。

要点

  • TalaDME研究评估ICG引导靶向激光联合抗VEGF能否减少TelCaps相关黄斑水肿第一年注射次数且视力非劣效。
  • 计划随机270只眼至抗VEGF单药组或联合IGTL组,按黄斑水肿病因(视网膜静脉阻塞 vs 糖尿病)分层。
  • 主要终点为12个月内注射次数及基线至12个月视力变化,次要终点包括黄斑中心厚度、生活质量、治疗费用和增量成本效用比。

核心结论

  • TalaDME旨在确立额外靶向激光的临床与医学经济学获益。
  • TalaDME结果可能提出黄斑水肿管理的新推荐并影响医疗费用。

研究设计与样本

  • TalaDME是一项法国多中心、两组、随机、假激光对照、双盲、非劣效性临床试验。
  • 计划纳入270例患者的270只眼,按1:1随机分为抗VEGF单药组(对照组)或联合IGTL组(试验组)。
  • 按黄斑水肿病因(视网膜静脉阻塞 vs 糖尿病)进行分层。

主要发现

  • 两组均先每月接受抗VEGF玻璃体腔注射3个月(负荷剂量),之后按需方案治疗并每月随访12个月。
  • 主要终点为12个月内玻璃体腔注射次数及基线至12个月视力变化。
  • 次要终点包括黄斑中心厚度变化、生活质量影响、治疗费用及各组增量成本效用比。

关键数值与推荐

  • 纳入标准为视网膜静脉阻塞或糖尿病视网膜病变继发的中心受累黄斑水肿且存在TelCaps的视力下降患者。
  • 假激光组在3个月时若研究者判断必要,可由非设盲研究者进行补救激光光凝。
  • TelCaps可能影响30%至60%的糖尿病视网膜病变或视网膜静脉阻塞所致慢性黄斑水肿患者。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为TalaDME结果可能提出黄斑水肿管理的新推荐并影响医疗费用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Macular edema (ME) results from hyperpermeability of retinal vessels, leading to chronic extravasation of plasma components into the retina and hence potentially severe visual acuity loss. Current standard of care consists in using intravitreal injections (IVI), which results in a significant medical and economic burden. During diabetic retinopathy (DR) or retinal vein occlusion (RVO), it has recently been shown that focal vascular anomalies (capillary macro-aneurysms, also termed TelCaps) for telangiectatic capillaries may play a central role in the onset, early recurrence, and/or persistence of ME. Since targeted photocoagulation of TelCaps may improve vision, identification, and photocoagulation of TelCaps, it may represent a way to improve management of ME. OBJECTIVE: The Targeted Laser in (Diabetic) Macular Edema (TalaDME) study aims to evaluate whether ICG-guided targeted laser (IGTL), in association with standard of care by IVI, allows reducing the number of injections during the first year of treatment compared with IVI only, while remaining non-inferior for visual acuity. METHODS: TalaDME is a French, multicentric, two-arms, randomized, sham laser-controlled, double-masked trial evaluating the effect of photocoagulation of TelCaps combined to IVI in patients with ME associated with TelCaps. Patients with vision loss related to center involved ME secondary to RVO or DR and presenting TelCaps are eligible. Two hundred and seventy eyes of 270 patients are randomized in a 1:1 ratio to standard care, i.e., IVI of anti-VEGF solely (control group) or combined with IGTL therapy (experimental group). Stratification is done on the cause of ME (i.e., RVO versus diabetes). Anti-VEGF IVI are administered to both groups monthly for 3 months (loading dose) and then with a pro re nata regimen with a monthly follow-up for 12 months. The primary endpoint will be the number of IVI and the change in visual acuity from baseline to 12 months. Secondary endpoints will be the changes in central macular thickness, impact on quality of life, cost of treatment, and incremental cost-utility ratio in each groups. KEY SAFETY: Rare but severe AE linked to the use of IVI and laser, and previously described, are expected. In the sham group, rescue laser photocoagulation may be administered by the unmasked investigator if deemed necessary at month 3. DISCUSSION: The best management of ME associated with TelCaps is debated, and there have been no randomized study designed to answer this question. Given the fact that TelCaps may affect 30 to 60% of patients with chronic ME due to DR or RVO, a large number of patients could benefit from a specific management of TelCaps. TalaDME aims to establish the clinical and medico-economic benefits of additional targeted laser. The results of TalaDME may raise new recommendations for managing ME and impact healthcare costs. TRIAL REGISTRATION: EudraCT: 2018-A00800-55/ NCT03751501. Registration date: Nov. 23, 2018.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Dupas B, Castro-Farias D, Girmens JF, et al. Photocoagulation or sham laser in addition to conventional anti-VEGF therapy in macular edema associated with TelCaps due to diabetic macular edema or retinal vein occlusion (TalaDME): a study protocol for a multicentric, French, two-group, non-commercial, active-control, observer-masked, non-inferiority, randomized controlled clinical trial. Trials. 2024. PMID: 38649937. doi:10.1186/s13063-024-07994-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。